37results about How to "Reduce ischemia-reperfusion injury" patented technology

The invention relates to a preservation solution for organs, tissues or cells of human bodies or animals. The organ preservation solution comprises sodium citrate, potassium citrate, magnesium sulfate, sodium dihydrogen phosphate, sodium hydroxide, adenosine, arginine, tryptophan, mannitol, tetramethylpyrazine hydrochloride and other components. The organ preservation solution can be used for cooling, lavaging and preserving the organs of the human bodies or the animals, can effectively preserve human in vitro kidneys for 48 hours and animal in vitro kidneys for 72 hours, can prevent ischemia-reperfusion injury, and has great value for clinical application.

The present invention relates to one kind of organ preserving fluid and its preparation process. Each 1000 ml of the organ preserving fluid contains 5 mol / L concentration NaOH solution 3 ml, hydroxyethyl starch 58.5-71.5 g, potassium lactobionate 37.08-45.32 g, MgSO4.7H2O 1.12-1.38 g, adenosine 1.61-1.97 g, allopurinol 0.13-0.16 g, KH2PO4 3.15-3.85 g, cane sugar 9.23-11.29 g, glutathione 0.92-1.12 g, diltiazem hydrochloride 20 mg, KOH and double distilled water in proper amount. The organ preserving fluid has pH 7.3-7.5. Its preparation process includes setting double distilled water in 800 ml in some container, adding the said components via stirring, regulating pH with KOH, adding double distilled water to 1000 ml, filtering and abacterial preservation at 0-8 deg.c.

The invention discloses two bromophenol compounds and a pharmaceutical application of their pharmaceutically-acceptable salts, specifically an application in the preparation of a myocardial ischemia-reperfusion injury protection drug. The two compounds and their pharmaceutically-acceptable salts can protect cardiomyocytes during rat heart acute ischemia so as to make rat heart functions complete.After routine intravenous administration, SOD activity after myocardial ischemia-reperfusion is raised, myocardial compliance is improved, serum LDH, serum CK, serum cTnT and MDA level after myocardial ischemia-reperfusion is remarkably reduced, myocardial injury is minimized, and FasmRNA after myocardial ischemia-reperfusion can be remarkably inhibited and reduced so as to inhibit cardiomyocyte apoptosis after myocardial ischemia-reperfusion. Therefore, the two bromophenol compounds and their pharmaceutically-acceptable salts have a clear myocardial ischemia-reperfusion injury protection function, thus providing a new method and means for the clinical treatment of myocardial ischemia-reperfusion injury and opening up a new direction for clinical medication.

Disclosed is a therapy for alleviating ischemia-reperfusion injury, which has few adverse side effects and can inhibit the invasion of neutrophils and the activation of platelets during ischemia reperfusion. The therapy comprises administering a mixed gas through inhalation to a patient who is intended to receive reperfusion, for a period between a time point that is immediately prior to the initiation of the ischemia-reperfusion and a time point that is shortly after the initiation of the reperfusion, wherein the mixed gas comprises 21 to 98% of oxygen, 0.1 to 4% of hydrogen and 40 to 80 ppm of nitrogen monoxide, with the remainder being an inert gas such as a nitrogen gas and a helium gas.

The invention provides an in-vitro-input-controllable balloon capable of reducing an ischemia reperfusion injury, and relates to the field of interventional medical apparatuses and instruments. The in-vivo-flow-controllable balloon capable of reducing the ischemia reperfusion injury is composed of a gas charging port, a hard pushing tube, a proximal soft tube, a balloon body, a distal soft tube, aguide wire and a flow control part, wherein the flow control part is composed of an outer perfusion joint and a flow controller connected on the outer perfusion joint through a catheter; controllableperfusion flow is achieved in an in-vitro-input-controllable manner; after the balloon is inflated, the balloon is not released, the in-vitro-input-controllable reperfusion balloon is controlled through the outer perfusion joint at the distal end of the balloon body and the flow controlled connected on the outer perfusion joint through the catheter, prepared perfusion fluid can be used for beingslowly perfused into the distal end of an infarction region or an ischemic region, and therefore the ischemia reperfusion injury is avoided; the balloon only needs one time of expansion and release while the distal end is subjected to perfusion, and blood vessel injuring, plaque falling and the distal blood-vessel no-reflowing phenomenon can be reduced or avoided.

The invention relates to the technical field of medical instruments and discloses a first-aid instrument for crush injury. The first-aid instrument comprises a microcontroller, a hemostasis air belt, a blood flow detecting device, a pressure device and a decompressing device. The blood flow detecting device is connected with the microcontroller and used for detecting blood flowing information in crush-injured limbs, transmitting blood blocking signals to the microcontroller when blood is blocked and transmitting blood flowing signals to the microcontroller when the blood flows. The pressure device is connected with the hemostasis air belt and the microcontroller and used for inflating the hemostasis air belt under the control the microcontroller to block blood flowing. The decompressing device is connected with the hemostasis air belt and the microcontroller and used for deflating the hemostasis air belt under the control of the microcontroller to recover blood flowing. The microcontroller is used for controlling the pressure device to inflate the hemostasis air belt and controlling the decompressing device to deflate the hemostasis air belt in circulation mode. By using a medical means of ischemic postconditioning, ischemia reperfusion damage on the crush-injured limbs after stress is removed is relieved, and a purpose of protecting the injured limbs is achieved.

The invention relates to a blood vessel anastomat which comprises a main body made from shape memory alloy. The main body is a tubular member, a tube wall is net-shaped, multiple deformable units areformed or defined among net lines of the main body, blood vessel inner wall fixing parts are arranged in the deformable units, the main body is changed from a closed-up state to an unfolded state forradial expansion and axial contraction after reaching phase-transition temperature, the deformable units are tight and the blood vessel inner wall fixing parts are located in the deformable units or are bent towards the inside of the main body when the main body is in the closed-up state, the deformable units expand to form rhombuses and the blood vessel inner wall fixing parts are turned out of the main body and sunken into the inner sides of blood vessel walls when the main body is in the unfolded state. By adopting the above scheme, the blood vessel anastomat performs suture without suturelines, ensures blood vessel smoothness and is easy and convenient to operate.

The invention discloses a solid beverage capable of improving dysmenorrhea in women. The solid beverage capable of improving dysmenorrhea in women is prepared from the following raw materials according to a certain weight ratio: fruits of plukenetia volubilislinneo, kudzuvine roots, linseeds, chia seeds, a haematococcus pluvialis extract, a rosemary extract, soybean isoflavones, probiotics, prebiotics, citric acid, brown sugar, and vitamins. The adopted raw materials interact so as to improve dysmenorrhea conditions from multiple aspects, as well as relieve uterine smooth muscle sensitivity caused by estrogen; and magnesium ion concentration in the uterine muscle cells is increased so as to decrease stimulation of external active substances on the uterine muscle cells, and thus, uterine smooth muscle tension is reduced so that the purpose of treating dysmenorrhea is achieved; moreover, production of prostaglandin PGF2-alpha, prostaglandin LT4 and free radicals which cause dysmenorrheaof the body is reduced, contracture of uterine smooth muscle is relived by reducing occurrence of ischemia-reperfusion injuries in the uterus, and intestinal flora are improved so as to raise absorption and utilization rates of active ingredients so that survival and growth of probiotics in the body are facilitated.

Disclosed herein are compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein A, X<1>, X<2>, R<1>, R<2>, R<3>, m, n, and p are defined in the specification. Compositions including the compounds which can be useful for inhibiting Rho kinase (ROCK) and methods for using the compositions are also described.

The invention discloses application of DUSP12 in hepatic ischemia reperfusion injury (IRI). A hepatocyte specific DUSP12 gene knockout mouse and a hepatocyte specific DUSP12 transgenic mouse are selected as test objects, mouse hepatic IRI models are constructed respectively, then isolated culture of primary hepatocytes and construction of hepatocyte in-vitro anoxia / reoxygenation are performed, and the function of DUSP12 in IRI is studied; and the new function of the DUSP12 gene in hepatic IRI is discovered, and DUSP12 overexpression can relieve hepatic IRI by inhibiting inflammation and cell apoptosis, so that the DUSP12 can be applied to screening or preparation of a drug for preventing / treating hepatic IRI, and a new drug target is provided for hepatic IRI.

The invention provides a liver perfusate, which is prepared by 5,500 to 6,500 mg / L of sodium chloride, 250 to 350 mg / L of potassium chloride, 150 to 250 mg / L of calcium chloride, 3,000 to 3,200 mg / L of sodium lactate, 4 to 6 mmol / L of 1, 6-diphosphofructose, 5 to 15 mg / L of dexamethasone, 2.5 to 3.5 mmol / L of reduced glutathione, and 4 to 6mg / L of verapamil. The product has a simple formula, convenient configuration, low cost and proper potassium concentration, can be safely used for the preservation of isolated organs, more importantly can be applied to the perfusion protection of in vivo organs, and can effectively prevent the injury of hepatic ischemia reperfusion. The invention also provides two preparation methods for the liver perfusate.

The invention aims to provide an in-vitro cardiopulmonary combined perfusion system and a perfusion method. The in-vitro organs are preserved by using an organ perfusion method, ischemia reperfusion injury caused by low-temperature preservation is avoided, and the problem that the in-vitro cardiopulmonary organs cannot be perfused and preserved at the same time is solved. The system comprises an organ cabin, a circulation cabin, a control cabin, a simple breathing cabin, a cardiac pacemaker body, a development and control panel and a base, the organ cabin is connected with the circulation cabin, the control cabin and the simple breathing cabin, and the control cabin is connected with the development and control panel. The organ cabin, the circulation cabin, the control cabin, the simple breathing cabin and the imaging and control panel are installed on the base, the simple breathing machine is placed in the simple breathing cabin, and the simple breathing machine and the cardiac pacemaker are respectively connected with the in-vitro cardiopulmonary to form an in-vitro cardiopulmonary support system. The cardiac pacemaker monitors and outputs a signal to the control cabin, and the control cabin controls the work of the cardiac pacemaker.

The invention relates to the technical field of medicine, in particular to saturated hydrogen saline water washing liquor and a preparation method and application thereof. The saturated hydrogen saline water washing liquor is a sodium chloride solution with the hydrogen concentration being 0.3-1.8 mmol / L. The invention further provides a preparation method of the washing liquor. The invention further provides application of the washing liquor. The washing liquor applies flushing mechanical strength to achieve the purpose of cleaning; hydrogen in the washing liquor can increase functions of oxidation resistance and inflammation resistance, it is beneficial for healing of inflammation, and a treatment role is played.

The invention relates to a device for rapid liver transplantation by combining glue and magnetism with an intravascular stent and a using method of the device. The device comprises the intravascular stent and an extravascular magnetic gel strip, wherein needle pricks are arranged in the middle of the outer wall of the intravascular stent, the extravascular magnetic gel strip is arranged on the outer side of the intravascular stent, magnetic particles are arranged in the extravascular magnetic gel strip, and the intravascular stent is an expandable stent. The extravascular magnetic gel strip ismade of polyacrylamide-alginate double-network gel, and the magnetic particles are made of nanometer ferroferric oxide. The device has the characteristics of being quick, safe and reliable.

The invention belongs to the technical field of medicines, and particularly relates to a hydrophilic nano-drug carrying beta-carotene and an application thereof in preparation of a drug for treating cerebral ischemia-reperfusion injury. According to the invention, the beta-carotene is carried by the high-molecular DSPE-PEG, so that the water solubility and the stability of the high-molecular DSPE-PEG are improved; an intrathecal injection method is used for increasing the aggregation of the nano-drug in the brain; beta-carotene is used for removing active oxygen, oxidative stress injury afterischemia-reperfusion of the brain is effectively reduced, the important value is achieved for developing medical application of beta-carotene, and the important significance is achieved for treating and relieving ischemia-reperfusion injury of the brain.

The invention relates to an advanced glycosylation end product CML as an early diagnosis marker of myocardial ischemia reperfusion injury and application thereof, and particularly discloses adoption of CML as an early diagnosis marker of myocardial ischemia reperfusion injury, and application of Pyridorin in inhibiting production of CML so as to relieve myocardial ischemia reperfusion injury. According to the invention, verified in animal level, the advanced glycosylation end product CML is remarkably increased after myocardial ischemia reperfusion, and therefore, myocardial ischemia reperfusion injury can be diagnosed and predicated by detecting the level of the advanced glycosylation end product CML in the peripheral blood of a testee individual or a sample of an in vitro myocardial tissue. By applying an inhibitor Pyridorin, myocardial ischemia reperfusion injury can be effectively relieved, and Pyridorin can be used as an active component for resisting against myocardial ischemia reperfusion injury to be used for preparing medicine for treating myocardial ischemia reperfusion injury. The invention provides a new effective target for diagnosis and treatment of myocardial ischemia reperfusion injury.

The invention relates to in-vitro lung mechanical perfusate, a preparation method and application thereof. The in-vitro lung mechanical perfusate comprises a basic medium, human serum albumin, polysucrose, dextran, mannitol and nitroglycerin; in the in-vitro lung mechanical perfusate, the concentration of the human serum albumin is 5g / L-20g / L, the concentration of the polysucrose is 25g / L-70g / L, the concentration of the dextran is 1g / L-50g / L, the concentration of the mannitol is 1g / L-15g / L, and the concentration of the nitroglycerin is 1g / L-20g / L. The in-vitro lung mechanical perfusate can keep the in-vitro lung function stable for a long time, relieve pulmonary edema, repair the lung, increase the utilization rate of the donor lung, reduce the use amount of albumin and greatly reduce thecost.

The invention provides a liver perfusate, which is prepared by 5,500 to 6,500 mg / L of sodium chloride, 250 to 350 mg / L of potassium chloride, 150 to 250 mg / L of calcium chloride, 3,000 to 3,200 mg / L of sodium lactate, 4 to 6 mmol / L of 1, 6-diphosphofructose, 5 to 15 mg / L of dexamethasone, 2.5 to 3.5 mmol / L of reduced glutathione, and 4 to 6mg / L of verapamil. The product has a simple formula, convenient configuration, low cost and proper potassium concentration, can be safely used for the preservation of isolated organs, more importantly can be applied to the perfusion protection of vivo organs, and can effectively prevent the injury of hepatic ischemia reperfusion. The invention also provides two preparation methods for the liver perfusate.

The invention discloses two bromophenol compounds and a pharmaceutical application of their pharmaceutically-acceptable salts, specifically an application in the preparation of a myocardial ischemia-reperfusion injury protection drug. The two compounds and their pharmaceutically-acceptable salts can protect cardiomyocytes during rat heart acute ischemia so as to make rat heart functions complete.After routine intravenous administration, SOD activity after myocardial ischemia-reperfusion is raised, myocardial compliance is improved, serum LDH, serum CK, serum cTnT and MDA level after myocardial ischemia-reperfusion is remarkably reduced, myocardial injury is minimized, and FasmRNA after myocardial ischemia-reperfusion can be remarkably inhibited and reduced so as to inhibit cardiomyocyte apoptosis after myocardial ischemia-reperfusion. Therefore, the two bromophenol compounds and their pharmaceutically-acceptable salts have a clear myocardial ischemia-reperfusion injury protection function, thus providing a new method and means for the clinical treatment of myocardial ischemia-reperfusion injury and opening up a new direction for clinical medication.

An exterior-applied baicalin medicine in the form of liquid or ointment is prepared from baicalin powder through proportionally mixing it with the water for injection, regulating pH=5.5-8.0, laying aside for at least one day, and filter to obtain liquid, or proportionally mixing it with medical alcohol, stirring, adding vaseline and stirring to obtain ointment. It can regulate immunity, protect liver and gallbladder, and treat infection and tumor.

The invention belongs to medical biology technology, and relates to an organ preservation solution and its preparation. According to the preparation steps per 1000ml, it comprises: taking 1.57mg of tetrahydrobiopterin and 6.92mg of diazoxide and dissolving them in 1ml of dimethyl sulfoxide As a mother liquor; prepare 0.1mol / L CaCl210ml for later use; add 800ml double distilled water into a 1000ml container, add KCl 1.12g, MgCl22.64g, mannitol 10.93g, histidine 4.63g, glutathione 0.92g, Sodium glutamate 3.74g, stir until clear; add sodium lactate 6.90ml, stir until clear; add 0.1mol / L CaCl22.5ml, stir until clear; add stock solution and mother liquor, stir until clear. The pH was adjusted to 7.3-7.5, the osmotic pressure was adjusted to 320Osm / L, and the volume was adjusted to 1000ml with double distilled water. Store at 4°C for low temperature storage.

The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases, which comprises ginseng stems and leaves saponin extracted from ginseng leaves and stems, and bilobalide extracted from ginkgo leaves.

The invention discloses a cryogenic preservation method and a recovery method without ice crystals in a supercooled state, and relates to the technical field of cryogenic medicine. The method for cryopreservation without ice crystals in a supercooled state includes: adding an oil substance to a cryoprotective solution in which cells or tissues are suspended, so that the oil substance completely covers the surface of the cryoprotectant solution to form a sample, and the sample is cryopreserved. The application can inhibit the freezing of cryoprotective solution at ‑20℃~0℃, and has obvious effects of inhibiting the formation of ice crystals and preventing the growth of ice crystals, so that the use of cytotoxic cryoprotective solutions such as DMSO can be avoided in tissue cell banks, etc. It is more conducive to the construction of a safe and non-toxic biological sample bank. This application can perform cryopreservation of tissue cells for a longer time (>2 days) at lower temperatures, reducing ischemia-reperfusion injury, and the survival rate of tissue cells after resuscitation is higher, and can maintain the original biological properties.

The invention relates to the technical field of medical instruments and discloses a first-aid instrument for crush injury. The first-aid instrument comprises a microcontroller, a hemostasis air belt, a blood flow detecting device, a pressure device and a decompressing device. The blood flow detecting device is connected with the microcontroller and used for detecting blood flowing information in crush-injured limbs, transmitting blood blocking signals to the microcontroller when blood is blocked and transmitting blood flowing signals to the microcontroller when the blood flows. The pressure device is connected with the hemostasis air belt and the microcontroller and used for inflating the hemostasis air belt under the control the microcontroller to block blood flowing. The decompressing device is connected with the hemostasis air belt and the microcontroller and used for deflating the hemostasis air belt under the control of the microcontroller to recover blood flowing. The microcontroller is used for controlling the pressure device to inflate the hemostasis air belt and controlling the decompressing device to deflate the hemostasis air belt in circulation mode. By using a medical means of ischemic postconditioning, ischemia reperfusion damage on the crush-injured limbs after stress is removed is relieved, and a purpose of protecting the injured limbs is achieved.

The invention belongs to the technical field of medicines, and particularly relates to a medicine for protecting the liver. The medicine for protecting the liver comprises the following components: 10%-35% of a kaurane diterpene compound (I)shown in the specification, 10%-35% triterpenoid (II) shown in the specification and the balance of a pharmaceutically acceptable carrier, wherein the sum of the percentages of the kaurane diterpene compound (I) and the triterpenoid (II) is 35%-70%. An in vitro test proves that the medicine is capable of relieving ischemia reperfusion injuries of human hepatocytes and playing a role in protecting the hepatocytes.

The invention discloses a hepatic portal blood flow blocking device, which relates to the field of clinical medicine, and comprises a catheter, a blocking bag and a positioning head. The base end of the catheter is provided with a protective plug to prevent external impurities from entering the catheter; At least one layer of flexible layer material, the inner surface of the flexible layer or in the flexible layer is provided with linear support frames arranged at intervals, and the support frames are made of shape memory alloy; the flexible layer surrounds the interior to form a cavity; the end of the cavity The positioning head is formed by a protrusion away from the catheter. The center of the positioning head is provided with a pinhole-shaped through hole connecting the outside to the cavity. The positioning head is also covered with an annular positioning ring. It realizes the ability to reduce the requirements for ultrasound-guided technology and puncture technology during use, and realizes simple and rapid blood flow occlusion in the hepatic portal vein, so as to implement precise resection. The technical effect of reducing the chance of portal vein metastasis and improving the survival rate of patients in the perioperative period after surgery.

The present invention provides a controllable external input balloon for reducing ischemia-reperfusion injury, which relates to the field of interventional medical devices. It consists of mass pushing tube, proximal flexible tube, balloon, distal flexible tube, guide wire and flow control components. The flow control component consists of an external perfusion joint and a flow controller connected to the external perfusion joint through a catheter; controllable perfusion flow; after the balloon is inflated, the balloon is not released, and the controllable reperfusion balloon is injected in vitro through the external perfusion joint at the distal end of the balloon and the flow controller connected to the external perfusion joint through a catheter To control, the prepared perfusion solution can be used to slowly perfuse the infarct area or the distal end of the ischemic area to avoid ischemia-reperfusion injury; while perfusing the distal end, the balloon only needs to be expanded and released once, which can reduce or avoid vascular injury, Plaque shedding and no-reflow in distal vessels occurred.

The invention discloses an ice-crystal-free low-temperature preservation method in a supercooled state and an ice-crystal-free low-temperature recovery method in the supercooled state, and relates to the technical field of low-temperature medicine. The ice-crystal-free low-temperature preservation method in the supercooled state comprises the following steps: adding an oil substance into a cryoprotectant in which cells or tissues are suspended, allowing the oil substance to completely cover the surface of the cryoprotectant to form a sample, and carrying out low-temperature preservation on the sample. According to the invention, the cryoprotectant can be inhibited from freezing at a temperature of -20 DEG C to 0 DEG C, and the obvious effects of inhibiting ice crystal formation and preventing ice crystal growth are obtained, so a tissue cell bank and the like can be prevented from using cryoprotectants with cytotoxicity, such as DMSO (dimethylsulfoxide), and a safe and non-toxic biological sample bank is more favorably constructed. Compared with the prior art, the methods of the invention have the advantages that tissue cell cryopreservation can be performed for a longer time (longer than 2 days) at a lower temperature, ischemia-reperfusion injury is relieved, the survival rate of tissue cells after resuscitation is higher, and original biological characteristics can be kept.

The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases, wherein the raw material includes the constituents of hippophe flavone 1 part, Notoginsen triterpenes 0.1-20 parts.

The invention provides a balloon controllable in in-vivo flow and capable of reducing ischemia reperfusion injury and relates to the field of intervention medical instruments. The balloon comprises atail-end joint, a hard pushing tube, a perfusion hose, a balloon body, a guide wire and a flow control part, and the flow control part is composed of an inner perfusion hole, a wrapping outer sheath and an inner perfusion hole mark. After the balloon is inflated, the far end of an infarction zone or an ischemia zone can be perfused accurately and slowly by sliding the wrapping outer sheath withoutreleasing the balloon so as to avoid the ischemia reperfusion injury; the balloon only needs to be expanded and released once while the far end is perfused, so that vascular injury, plaque shedding and no-reflow of blood vessels at the far end can be reduced or avoided.